ErbB4 promotes cyclooxygenase-2 expression and cell survival in colon epithelial cells

Laboratory Investigation

Volumn 90, Issue 10, 2010, Pages 1415-1424

  Frey, Mark R ^a   Hilliard, Valda C ^a   Mullane, Matthew T ^a   Polk, D Brent ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cell survival; colon epithelial cells; cyclooxygenase 2; ErbB4; inflammatory bowel diseases; receptor tyrosine kinases

Indexed keywords

CELL PROTEIN; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 4; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN SRC; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL SURVIVAL; COLON MUCOSA; EPITHELIUM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 77957282682     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2010.117     Document Type: Article

References (45)

1. Srinivasan R, Poulsom R, Hurst HC, et al. Expression of the c-erbB-4/ HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types. J Pathol 1998;185:236-245. (Pubitemid 28320044)
2. Linggi B, Cheng QC, Rao AR, et al. The ErbB-4 s80 intracellular domain is a constitutively active tyrosine kinase. Oncogene 2006;25:160-163. (Pubitemid 43050015)
3. Long W, Wagner K-U, Lloyd KCK, et al. Impaired differentiation and lactational failure of Erbb4-deficient mammary glands identify ERBB4 as an obligate mediator of STAT5. Development 2003;130:5257-5268. (Pubitemid 37369683)
4. Vaskovsky A, Lupowitz Z, Erlich S, et al. ErbB-4 activation promotes neurite outgrowth in PC12 cells. J Neurochem 2000;74:979-987. (Pubitemid 30104293)
5. Erlich S, Goldshmit Y, Lupowitz Z, et al. ErbB-4 activation inhibits apoptosis in PC12 cells. Neuroscience 2001;107:353-362. (Pubitemid 33145357)
6. Kainulainen V, Sundvall M, Maatta JA, et al. A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis. J Biol Chem 2000;275: 8641-8649. (Pubitemid 30180214)
7. Tang CK, Goldstein DJ, Payne J, et al. ErbB-4 ribozymes abolish neuregulin-induced mitogenesis. Cancer Res 1998;58:3415-3422. (Pubitemid 28371084)
8. Ni CY, Murphy MP, Golde TE, et al. gamma-Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 2001; 294:2179-2181. (Pubitemid 33150677)
9. Srinivasan R, Gillett CE, Barnes DM, et al. Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers. Cancer Res 2000;60:1483-1487. (Pubitemid 30183410)
10. Starr A, Greif J, Vexler A, et al. ErbB4 increases the proliferation potential of human lung cancer cells and its blockage can be used as a target for anti-cancer therapy. Int J Cancer 2006;119:269-274. (Pubitemid 43911889)
11. Carpenter G. ErbB-4: mechanism of action and biology. Exp Cell Res 2003;284:66-77. (Pubitemid 36331966)
12. Kaushansky A, Gordus A, Budnik BA, et al. System-wide investigation of ErbB4 reveals 19 sites of Tyr phosphorylation that are unusually selective in their recruitment properties. Chem Biol 2008;15:808-817.
13. Frey MR, Edelblum KL, Mullane MT, et al. The ErbB4 growth factor receptor is required for colon epithelial cell survival in the presence of TNF. Gastroenterology 2009;136:217-226.
14. Lee D, Yu M, Lee E, et al. Tumor-specific apoptosis caused by deletion of the ERBB3 pseudo-kinase in mouse intestinal epithelium. J Clin Invest 2009;119:2702-2713.
15. Gilroy DW, Colville-Nash PR, Willis D, et al. Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 1999;5:698-701. (Pubitemid 29289435)
16. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995;83:493-501.
17. Sun Y, Tang XM, Half E, et al. Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome cdependent apoptotic pathway in human colon cancer cells. Cancer Res 2002;62:6323-6328. (Pubitemid 35244488)
18. Singer II, Kawka DW, Schloemann S, et al. Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. Gastroenterology 1998;115:297-306. (Pubitemid 28363422)
19. Buchanan FG, Holla V, Katkuri S, et al. Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer. Cancer Res 2007;67:9380-9388. (Pubitemid 47535928)
20. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87:803-809. (Pubitemid 26404280)
21. Whitehead RH, VanEeden PE, Noble MD, et al. Establishment of conditionally immortalized epithelial cell lines from both colon and small intestine of adult H-2Kb-tsA58 transgenic mice. Proc Natl Acad Sci USA 1993;90:587-591.
22. Whitehead RH, Zhang HH, Hayward IP. Retention of tissue-specific phenotype in a panel of colon carcinoma cell lines: relationship to clinical correlates. Immunol Cell Biol 1992;70(Part 4):227-236.
23. Tong X, Yin L, Joshi S, et al. Cyclooxygenase-2 regulation in colon cancer cells: modulation of RNA polymerase II elongation by histone deacetylase inhibitors. J Biol Chem 2005;280:15503-15509. (Pubitemid 40616665)
24. Tang X, Sun YJ, Half E, et al. Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells. Cancer Res 2002;62:4903-4908. (Pubitemid 34984412)
25. Parfenova H, Balabanova L, Leffler CW. Posttranslational regulation of cyclooxygenase by tyrosine phosphorylation in cerebral endothelial cells. Am J Physiol 1998;274(1 Part 1):C72-C81. (Pubitemid 28099345)
26. Pinkas-Kramarski R, Shelly M, Guarino BC, et al. ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network. Mol Cell Biol 1998;18:6090-6101. (Pubitemid 28450560)
27. Mukhopadhyay D, Houchen CW, Kennedy S, et al. Coupled mRNA stabilization and translational silencing of cyclooxygenase-2 by a novel RNA binding protein, CUGBP2. Mol Cell 2003;11:113-126. (Pubitemid 36126595)
28. Sengupta S, Jang BC, Wu MT, et al. The RNA-binding protein HuR regulates the expression of cyclooxygenase-2. J Biol Chem 2003;278: 25227-25233. (Pubitemid 37548687)
29. Sureban SM, Ramalingam S, Natarajan G, et al. Translation regulatory factor RBM3 is a proto-oncogene that prevents mitotic catastrophe. Oncogene 2008;27:4544-4556.
30. Wright K, Kolios G, Westwick J, et al. Cytokine-induced apoptosis in epithelial HT-29 cells is independent of nitric oxide formation. Evidence for an interleukin-13-driven phosphatidylinositol 3-kinasedependent survival mechanism. J Biol Chem 1999;274:17193-17201. (Pubitemid 129519054)
31. Srinivasan R, Benton E, McCormick F, et al. Expression of the c-erbB-3/ HER-3 and c-erbB-4/HER-4 growth factor receptors and their ligands, neuregulin-1 alpha, neuregulin-1 beta, and betacellulin, in normal endometrium and endometrial cancer. Clin Cancer Res 1999;5: 2877-2883. (Pubitemid 29493966)
32. Soung YH, Lee JW, Kim SY, et al. Somatic mutations of the ERBB4 kinase domain in human cancers. Int J Cancer 2006;118:1426-1429. (Pubitemid 43306528)
33. Memon AA, Sorensen BS, Melgard P, et al. Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients. Br J Cancer 2004;91:2034-2041. (Pubitemid 40128770)
34. Rotterud R, Nesland JM, Berner A, et al. Expression of the epidermal growth factor receptor family in normal and malignant urothelium. BJU Int 2005;95:1344-1350. (Pubitemid 40799457)
35. Edwards J, Traynor P, Munro AF, et al. The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer. Clin Cancer Res 2006;12:123-130. (Pubitemid 43166185)
36. Junttila TT, Sundvall M, Lundin M, et al. Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. Cancer Res 2005;65:1384-1393. (Pubitemid 40270166)
37. Tovey SM, Witton CJ, Bartlett JM, et al. Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling. Breast Cancer Res 2004;6:R246-R251.
38. Lee JC, Wang ST, Chow NH, et al. Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery. Eur J Cancer 2002;38:1065-1071.
39. Leung SP, Griffith OL, Masoudi H, et al. Clinical utility of type 1 growth factor receptor expression in colon cancer. Am J Surg 2008;195:604-610. (Pubitemid 351522200)
40. Chuu CP, Chen RY, Barkinge JL, et al. Systems-level analysis of ErbB4 signaling in breast cancer: a laboratory to clinical perspective. Mol Cancer Res 2008;6:885-891.
41. McCole DF, Keely SJ, Coffey RJ, et al. Transactivation of the epidermal growth factor receptor in colonic epithelial cells by carbachol requires extracellular release of transforming growth factor-alpha. J Biol Chem 2002;277:42603-42612.
42. Xu KP, Yin J, Yu FS. Lysophosphatidic acid promoting corneal epithelial wound healing by transactivation of epidermal growth factor receptor. Invest Ophthalmol Vis Sci 2007;48:636-643. (Pubitemid 351260695)
43. Caruso R, Pallone F, Fina D, et al. Protease-activated receptor-2 activation in gastric cancer cells promotes epidermal growth factor receptor trans-activation and proliferation. Am J Pathol 2006;169: 268-278.
44. Chen X, Levkowitz G, Tzahar E, et al. An immunological approach reveals biological differences between the two NDF/heregulin receptors, ErbB-3 and ErbB-4. J Biol Chem 1996;271:7620-7629. (Pubitemid 26107041)
45. Hollmen M, Maatta JA, Bald L, et al. Suppression of breast cancer cell growth by a monoclonal antibody targeting cleavable ErbB4 isoforms. Oncogene 2009;28:1309-1319.